Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies.

Our Iomab-B and Actimab-A advanced product candidates fill the major unmet medical needs in relapsed or refractory AML in a complementary fashion directed at different parts of the patient journey. Iomab-B is being developed as a targeted bridging therapy candidate that we believe could provide both disease control and conditioning in one agent. Actimab-A is a targeted therapy that has demonstrated the potential to extend survival outcomes for people with r/r AML and is poised for advanced development in collaboration with the National Cancer Institute. Together, we believe these two product candidates could provide us the opportunity to transform the treatment of AML, especially in the relapsed and refractory segment which represents over 50% of AML patients. Based on early clinical trial results, we are also developing our Iomab-ACT program – a lower dose, next generation conditioning program for rapidly growing cell and gene therapies.

Our differentiated R&D efforts and our platform has been used to develop a pipeline of novel radiotherapeutic assets to drive company growth. We are continuing to expand our drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors. Our intellectual property portfolio includes more than 220 patents and patent applications worldwide.